BioSpace News Archive

FEND Administration Lowered Exhaled Particles in Subjects Including Healthy Subjects and a COVID-19 Patient Partner Sensory Cloud to Distribute FEND Worldwide, with Pulmatrix Receiving Escalating Royalties upon Commencement of Sales [30-September-2020] LEXINGTON, Mass. , Sept. 30, 2020 /PRNewswire/ – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage bioph

Thrive Earlier Detection Corp., a company dedicated to incorporating earlier cancer detection into routine medical care, today announced it has strengthened its leadership team with key appointments. Sam Asgarian, M.D., has been appointed to chief medical officer and Frank Diehl, Ph.D., as executive vice president of product solutions. Dina Ciarimboli, f

Reven Selects eClinical Services Provider DSG for Clinical Data Management Services to Accelerate the Clinical Development of Reven’s Investigational Drug Product RJX as a Treatment Against COVID-19 GOLDEN, Colo.--( BUSINESS WIRE )-- Reven Holdings, Inc. (“Reven”) is a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnesses—including COVID-19

-- New Findings on Biktarvy ® to Include Long-term Switch Studies as well as Real-World Data and Patient Reported Outcomes from the BICSTaR Study -- -- Data Evaluating Drug Resistance in People Receiving Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor, as Part of a Long-acting HIV Treatment Regimen to be Presented -- FOSTER CITY, Calif.--( BUSINESS WIRE )-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming

Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that it will present new preliminary data from the Phase I/II TEM-GBM study of Temferon™ in patients affected with glioblastoma multiforme, at the 4 th Virtual Annual Genetic Medicines Conference , hosted by Chardan on 5 th and 6 th of October 2020. Pierluigi Parac

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session on Oct. 5 as part of the Roth Capital Partners’ CEO Talk Series.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised its first contract option valued at $10.5 million.

OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, will participate in a virtual presentation and fireside chat at the October 2020 Lytham Partners Virtual Inv

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four presentations on amyotrophic lateral sclerosis (ALS) will be shared as part of the Northeast Amyotrophic Lateral Sclerosis (NEALS) 19 th Annual Meeting, being held virtually Sept. 30 – Oct. 1, 2020 . The data provide deeper insight into U.S. experience wit

Tornado Spectral Systems Inc., a leading manufacturer of Raman analyzers for process monitoring, is proud to announce that it has achieved ISO 9001:2015 certificatio